Introduction
============

COPD, a chronic inflammatory airway condition associated with episodes of acute deterioration termed exacerbations,[@b1-copd-10-759] is a major cause of chronic morbidity and mortality worldwide.[@b2-copd-10-759] The natural history of COPD is interrupted by episodes of worsening symptoms and signs of accelerating lung function decline[@b3-copd-10-759],[@b4-copd-10-759] leading to decreases in health-related quality of life,[@b5-copd-10-759],[@b6-copd-10-759] increased mortality,[@b7-copd-10-759],[@b8-copd-10-759] and health care costs.[@b9-copd-10-759],[@b10-copd-10-759] The Global initiative for chronic Obstructive Lung Disease (GOLD) is a collaborative project of the US National Heart, Lung, and Blood Institute and the World Health Organization. Its goals are to increase awareness of COPD and decrease morbidity and mortality from this disease by improving prevention and management of COPD.[@b11-copd-10-759] Care for many chronic health conditions including COPD is delivered by both specialists and generalists. Differences in patients' quality of care and management between generalists and specialists have been well documented for asthma,[@b12-copd-10-759]--[@b14-copd-10-759] whereas a few studies for COPD reported no differences.[@b15-copd-10-759]--[@b17-copd-10-759] In Thailand, health care utilization and hospital outcomes of COPD patients managed by pulmonologists and internists have never been studied. We hypothesized that patients managed by pulmonologists will be treated according more closely to GOLD guidelines, and will have less severe exacerbations, more favorable health care utilization, and better hospital outcomes.

Materials and methods
=====================

Study design
------------

This is a prospective, comparative observational study among COPD patients who were regularly managed by pulmonologists and internists at the two outpatient clinics, a pulmonologist clinic (Group A) and a general internal medicine clinic (Group B) of Department of Internal Medicine, Faculty of Medicine, Chiang Mai University Hospital, Chiang Mai, Thailand, from August 1, 2009 to July 31, 2010. Group A COPD patients were selected from out- or inpatient services of the department for further investigations and/or management judged by internists. Group B COPD patients were referred from community or provincial hospitals in the northern part of Thailand attended by general internal medicine rotating internists. Eligible patients were required to meet the criteria for COPD diagnosis as follows: current smokers or ex-smokers with a smoking history ≥10 pack-years, onset of breathlessness after 40 years of age, a ratio of post-bronchodilator (BD) forced expiratory volume in the first second (FEV~1~) to forced vital capacity less than 0.7 performed in accordance with guidelines of the American Thoracic Society and the European Respiratory Society,[@b18-copd-10-759] and a normal or abnormal chest radiograph compatible with the disease. All eligible COPD patients received confirmation diagnosis by a pulmonologist at our pulmonary function test laboratory and were regularly managed at either pulmonologist or general internal medicine clinic for at least 12 months prior to enrollment. Patients were excluded if they were diagnosed with asthma at age less than 40 years, visited both a general internal medicine and a pulmonologist clinic, were followed up at the clinics for less than 1 year, visited clinic irregularly or were lost to follow-up at the clinics, or were referred to other hospitals. All eligible patients were advised to come to the emergency department or clinics before routine appointment dates in case they felt deterioration of their respiratory symptoms. Six pulmonologists and two supervised pulmonary fellows provided care for Group A patients; Group B patients were attended by 25 rotating internists (qualified as generalists and in residency training for Thai Board of Internal Medicine). Internists were supervised by rotating general internal medicine staff, and details of pulmonologists and internists are shown in [Table 1](#t1-copd-10-759){ref-type="table"}. During the study period, patients had regular routine follow-up visits at 1-month to 3-month intervals with their physicians. Data reviewed from physician-maintained records include documentation of symptoms, onset and duration of disease, age of disease onset, tobacco use, % predicted of post-BD FEV~1~, GOLD staging, comorbidities, use of reliever and controller medications, influenza vaccine prescription, education on self-management plan and instructions for air pollution avoidance, and completion of a course of pulmonary rehabilitation (Suandok exercise training program).[@b19-copd-10-759] Acute exacerbation (AE) was defined as physician-diagnosed worsening of two or more of the following major symptoms for ≥2 consecutive days dispend, sputum volume, and sputum purulence requiring treatment with systemic corticosteroids and/or antibiotics without new pulmonary infiltration on chest radiographs.[@b1-copd-10-759] Severe AE was defined as any hospitalization related to COPD. The episodes and possible causes of severe AE were assessed from physician's medical records. Health care resource utilization, hospital length of stay, and costs of care were reviewed using hospital databases. Evaluation of COPD management between the two groups was based on adherence to international GOLD guidelines[@b11-copd-10-759] using pharmacological, non-pharmacological, and educational parts. The study protocol was approved by the Ethics Committees of the Faculty of Medicine, Chiang Mai University.

Statistical analysis
--------------------

The aim of this study was to compare consistency with international guidelines, between pulmonologists and internists using rate, health care utilization, and hospital outcomes of severe AE of COPD patients managed by pulmonologists and internists. Results for numerical values were expressed as mean ± standard deviation, and those for categorical data were expressed as absolute frequencies and percentages. Categorical variables were analyzed using Fisher's exact test, while continuous variables were compared using Mann--Whitney *U*-test. Statistical significance was set at *P*\<0.05. All analyses were conducted using the SPSS statistical package, version 16 for Windows.

Results
=======

Characteristics of the two groups of physicians are shown in [Table 1](#t1-copd-10-759){ref-type="table"}. The mean age and experience in internal medicine of physicians in Group A were higher than those in Group B (*P*\<0.001).

Out of a total of 310 patients diagnosed with COPD, 208 patients (137 in Group A and 71 in Group B) were eligible for the study ([Figure 1](#f1-copd-10-759){ref-type="fig"}). The characteristics of patients excluded due to irregular clinical visits were not different from their groups. Characteristics of the two groups of patients are shown in [Table 2](#t2-copd-10-759){ref-type="table"}. Distribution by age and sex was similar in both groups. Body mass index (BMI) in Group B was higher than Group A. Patients in Group A had a longer duration of disease and an earlier age of disease onset. In addition, patients in Group A had more severe impairment of pulmonary function in terms of mean post-BD FEV~1~ and GOLD stages. Evaluation of comorbidities also revealed that diabetes mellitus and dyslipidemia were more often addressed in Group B than Group A. Rates (%) and frequencies (patient-years) of severe AE were significantly lower in Group A ([Table 2](#t2-copd-10-759){ref-type="table"}).

The study assessed three parts of COPD management: pharmacological management, non-pharmacological management, and education ([Table 3](#t3-copd-10-759){ref-type="table"}). Regarding pharmacological management, the uses of controller medications between the two groups were significantly different. Fixed combinations of short-acting beta-2 agonist plus short-acting anticholinergic in the same device were more frequently prescribed in Group B. In contrary, the use of triple therapy (combined use of inhaled corticosteroid and long-acting beta-2 agonist, with long-acting anticholinergic) was more frequently prescribed in Group A. However, there was no difference in overall optimal pharmacological management based on GOLD stages between the two groups. Documentations on the use of other reliever and controller medications were similar in both groups. For non-pharmacological treatment, Group A received annual influenza vaccination and pulmonary rehabilitation more often than Group B. Overall, assessed non-pharmacological management measures corresponding to GOLD stages were significantly higher in Group A, as well as completed education on self-management plan and instruction for air pollution avoidance ([Table 3](#t3-copd-10-759){ref-type="table"}).

Characteristics of severe AE in both groups, 17 from each group, were similar in terms of age, sex, BMI, smoking status, age of disease onset, disease severity, comorbidities, and pharmacological and non-pharmacological managements except that Group A used more triple therapy and had greater knowledge on self-management plan and air pollution avoidance ([Table 4](#t4-copd-10-759){ref-type="table"}). Median time from onset of AE to admission tended to be shorter among Group A patients. Lower respiratory tract infection was more common in Group A, and air pollution exposure was more common in Group B. There was no statistically significant difference in the hospital length of stay and hospital costs between the two groups ([Table 5](#t5-copd-10-759){ref-type="table"}).

No significant difference in hospital death was found; however, the readmission rate with pneumonia in Group B was significantly higher ([Table 6](#t6-copd-10-759){ref-type="table"}).

Severe AE patients requiring mechanical ventilation were further explored ([Table 7](#t7-copd-10-759){ref-type="table"}). Mean mechanical ventilation days, as well as length of stays, were shorter in Group A. In contrast, costs of chest radiography and total costs of hospitalization were significantly higher in Group B. The costs for drugs, laboratory tests, and room with nursing service for treatment tended to be higher in Group B.

Discussion
==========

The pulmonologists in this study had much more experience in internal medicine than internist. Although the pharmacological management corresponding to the guidelines was not significantly different between the two groups, Group B received a combination of short-acting beta-2 agonist and short-acting anticholinergic in a single device as a controller more often than Group A, and Group A received triple therapy more often than Group B. The different patterns of pharmacological use were likely due to the differences in disease severity stages between the two groups. Group B had a higher proportion of GOLD stage I patients than Group A (21.1% vs 5.8%); the internists, therefore, would preferentially use a short-acting bronchodilator as a controller. In contrast, Group A had a higher proportion of GOLD stage IV patients than Group B (20.4% vs 8.5%); the pulmonologists would preferentially use triple therapy for them. It was possible that patients with severe or unable-to-control disease be referred from internists to pulmonologists for specialized management very early in their treatment cycle. This could be reflected from the findings that patients in Group A had a longer duration of illness and more severe disease as presented by lower FEV~1~ than those in Group B. In contrast, a non-pharmacological management was strikingly different. Rates of annual influenza vaccination and pulmonary rehabilitation were significantly greater in Group A. Although care by pulmonologists appeared to be better than that by internists on annual influenza vaccination and pulmonary rehabilitation, there were also opportunities for enhancement with regard to compliance with guidelines for both groups. Despite a national health policy that provides free annual influenza vaccinations, the rates of vaccination were quite low in both groups. Pulmonary rehabilitation was a highly effective and safe intervention to reduce hospital admissions and mortality, and to improve the health-related quality of life in COPD patients.[@b20-copd-10-759] We found a significantly lower referral for pulmonary rehabilitation by internists than pulmonologists; however, both groups were still far from optimal in comparison to guidelines. Patients managed by internists had no referral to pulmonary rehabilitation which has not changed from our previous study conducted several years ago.[@b21-copd-10-759] Indeed, a systematic review[@b22-copd-10-759] had also found that referral rates to pulmonary rehabilitation were 3%--18% then, which are in the same range as in our current study. The process of referral even by pulmonologists was often complex and includes barriers such as lack of awareness, engagement at multiple levels, and time consumed as well as perceived difficulty of the referral process.[@b23-copd-10-759],[@b24-copd-10-759] Concerning education, Group A patients received more education on self-management and air pollution avoidance than Group B. The beneficial effect of education on air pollution avoidance might reflect the study result that the possible cause of severe AE from air pollution was significantly less in Group A. These findings on COPD management are in agreement with previous studies showing inconsistency with guidelines for COPD by internists and the benefits of using pulmonologists in the delivery of COPD care.[@b25-copd-10-759]

Significantly lower rates and frequencies of severe AE were found in Group A, despite the fact that it had higher numbers of disease severity. Although, hospital length of stay and costs of care for severe AE were not significantly different, but those requiring mechanical ventilation in Group B had significantly longer length of stay and higher hospital cost. Our findings contrasted with previous studies where there are no differences in outcome or costs of care for COPD regardless of the source of care,[@b14-copd-10-759],[@b15-copd-10-759],[@b17-copd-10-759] and one of the previous studies did not identify any differences in hospital length of stay between patients managed by pulmonologists and internists.[@b14-copd-10-759] We also evaluated hospital mortality and readmission with pneumonia, and found no differences in the mortality rates between the two groups. This finding is similar to previous studies.[@b14-copd-10-759],[@b15-copd-10-759] However, this study found statistically significant higher hospital readmission with pneumonia in the group managed by internists which is a contradiction to previous studies.[@b14-copd-10-759],[@b15-copd-10-759] There were limitations to this study. Firstly, we did not assess the level of education, health status, or history of AE of the patients in each group that might confound the study results. Secondly, only patients followed up by pulmonologists and internists were studied but not those cared for by other types of generalists, such as family doctors or general practitioners. Thirdly, this study was done in a university hospital, and its results may not be generalizable to other health care institutions. Fourthly, the episodes of severe AE in the study were relatively low, which was probably due to the strict study inclusion criteria defined to enroll only compliant patients with every scheduled visit at least a year prior to enrollment. The small sample size may also affect the statistical result; some differences (eg, mortality, length of stay, cost) are numerically important but not statistically significant.

The results of our study demonstrated that there was an opportunity for cross fertilization of knowledge and practice patterns across clinicians so that all patients could receive evidence-based care in the most efficient manner. Increasing numbers of pulmonologists as the sole care provider for COPD patients is not feasible, especially in developing countries. COPD patients would benefit greatly from a multidisciplinary approach for COPD care delivery, whereas the pulmonologists would complement or reinforce what the internists have managed. In order to study the management of AE patients, strategies should be developed including setting up a prospective multicenter audit.

Conclusion
==========

There were differences in the management processes of COPD between pulmonologists and internists. In general, management by pulmonologists was in accordance with national COPD guidelines more than by internists, particularly in influenza vaccination, pulmonary rehabilitation, and education. The rates and frequencies of severe AE were significantly lower in patients managed by pulmonologists, and length of hospital stay and cost were significantly lower among the patients with severe AE who required mechanical ventilation. Although there was no statistical difference in hospital mortality due to severe AE, the readmission rate with pneumonia was significantly higher in patients managed by internists.

The authors wish to acknowledge the staff members of the Division of Pulmonary, Critical Care and Allergy, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, for their contribution to this trial.

**Author contributions**

The first author developed the study design and carried out acquisition and interpretation of data, statistical analysis, manuscript preparation, and critical revision of intellectual contents. The other authors contributed to acquisition and interpretation of data, revision of the article for important intellectual contents, and final approval of the version to be published.

**Disclosure**

The authors have no conflicts of interest in connection with this work.

![Flowchart showing participation throughout the study.](copd-10-759Fig1){#f1-copd-10-759}

###### 

Characteristics of pulmonologists and internists involved in this study

  Variables                                 Pulmonologist   Internists   *P*-value
  ----------------------------------------- --------------- ------------ -------------
  Age (years)                               40.1±6.8        28.4±2.0     \<**0.001**
  Male sex                                  7 (87.5)        12 (48.0)    **0.049**
  Experience in internal medicine (years)   12.6±7.2        3.6±1.4      \<**0.001**

**Notes:** Results are expressed as mean ± standard deviation or n (%). Bold values indicate *P*-value reached statistical significance (\<0.05).

###### 

Characteristics of COPD patients in Group A and Group B

  Variables                              Pulmonologist (Group A)   Internists (Group B)   *P*-value
  -------------------------------------- ------------------------- ---------------------- -------------
  Age (years)                            72.9±8.6                  70.6±8.8               0.307
  Male sex                               77 (56.2)                 44 (62.0)              0.424
  Body mass index (kg/m^2^)              20.2±3.7                  21.9±5.2               **0.016**
  Current smoker                         10 (7.3)                  8 (11.3)               0.523
  Duration of symptom (years)            8.8±6.7                   6.3±5.2                **0.031**
  Duration from diagnosis (years)        8.1±6.7                   3.4±4.1                \<**0.001**
  Age of disease onset (years)           63.7±10.1                 67.2±9.6               **0.048**
  \% predicted of post-BD FEV~1~         47.4±17.6                 61.0±25.1              \<**0.001**
  GOLD staging                                                                            
   I                                     8 (5.8)                   15 (21.1)              **0.020**
   II                                    52 (38.0)                 29 (40.8)              
   III                                   49 (35.8)                 21 (29.6)              
   IV                                    28 (20.4)                 6 (8.5)                
  Comorbidities                                                                           
   Diabetes mellitus                     10 (7.3)                  14 (19.7)              **0.008**
   Hypertension                          54 (39.4)                 35 (49.3)              0.172
   Dyslipidemia                          22 (16.1)                 21 (29.6)              **0.022**
   Chronic kidney disease                9 (6.6)                   5 (7.0)                0.897
   Coronary artery disease               12 (87.3)                 9 (12.7)               0.374
   Malignancy                            8 (5.8)                   3 (4.2)                0.622
  Severe AE                                                                               
   Rate                                  17 (12.4)                 17 (23.9)              **0.033**
   Number of severe AE (patient-years)   0.20±0.63                 0.41±0.80              **0.029**

**Notes:** Results are expressed as mean ± standard deviation or n (%). Bold values indicate *P*-value reached statistical significance (\<0.05).

**Abbreviations:** BD, bronchodilator; FEV~1~, forced expiratory volume in the first second; GOLD, Global initiative for chronic Obstructive Lung Disease; AE, acute exacerbation.

###### 

Use of COPD medications in Group A and Group B

  Variables                                                             Pulmonologist (Group A)   Internists (Group B)   *P*-value
  --------------------------------------------------------------------- ------------------------- ---------------------- -------------
  Pharmacological management                                                                                             
   Reliever                                                                                                              
    Combined SABA + SAAC                                                136 (99.3)                71 (100)               0.471
   Controller                                                                                                            
    Combined SABA + SAAC                                                5 (3.6)                   12 (16.9)              **0.001**
    LAAC alone                                                          7 (5.1)                   1 (1.4)                0.070
    ICS alone                                                           0 (0)                     1 (1.4)                0.452
    Combined ICS + LABA                                                 69 (50.4)                 48 (67.6)              0.337
    Triple therapy (ICS + LABA + LAAC)                                  56 (40.9)                 9 (12.7)               \<**0.001**
    Methylxanthines                                                     97 (70.8)                 45 (63.4)              0.275
  Optimal pharmacological treatment corresponding to GOLD stages        136 (99.3)                69 (97.2)              0.231
   I                                                                    8 (100.0)                 15 (100.0)             
   II                                                                   52 (100.0)                28 (96.6)              
   III                                                                  49 (100.0)                21 (100.0)             0.231
   IV                                                                   27 (96.4)                 5 (83.3)               
  Non-pharmacological management                                                                                         
   LTOT                                                                 20 (14.6)                 9 (12.7)               0.704
   Influenza vaccination in the past year                               43 (31.4)                 7 (9.9)                \<**0.001**
   Completion of pulmonary rehabilitation                               33 (24.1)                 0 (0.0)                \<**0.001**
  Optimal non-pharmacological management corresponding to GOLD stages   42 (30.7)                 7 (9.9)                **0.001**
  Education                                                                                                              
   Self-management plan                                                 93 (67.9)                 0 (0.0)                \<**0.001**
   Air pollution avoidance                                              137 (100.0)               12 (16.9)              \<**0.001**

**Notes:** Results are expressed as n (%). Bold values indicate *P*-value reached statistical significance (\<0.05).

**Abbreviations:** SABA, short-acting beta-2 agonist; SAAC, short-acting anticholinergic; LAAC, long-acting anticholinergic; ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonist; GOLD, Global initiative for chronic Obstructive Lung Disease; LTOT, long-term oxygen therapy.

###### 

Use of medications in COPD patients with severe acute exacerbation

  Variables                             Pulmonologist (Group A)   Internists (Group B)   *P*-value
  ------------------------------------- ------------------------- ---------------------- -----------
  Reliever                                                                               
   Combined SABA + SAAC                 17 (100.0)                17 (100.0)             --
  Controller                                                                             
   Combined SABA + SAAC                 0 (0.0)                   2 (11.8)               0.145
   LAAC alone                           1 (5.8)                   0 (0.0)                0.310
   Combined ICS + LABA                  10 (58.8)                 14 (82.4)              0.545
   Triple therapy                       6 (30.4)                  1 (5.8)                **0.034**
   Methylxanthines                      15 (88.2)                 13 (76.5)              0.368
  Other managements                                                                      
   LTOT                                 6 (35.3)                  7 (41.2)               0.724
   Influenza vaccine in the past year   1 (5.9)                   2 (11.8)               0.545
   Rehabilitation                       1 (5.9)                   0 (0.0)                0.310

**Notes:** Results are expressed as n (%). Bold value indicates *P*-value reached statistical significance (\<0.05).

**Abbreviations:** SABA, short-acting beta-2 agonist; SAAC, short-acting anticholinergic; LAAC, long-acting anticholinergic; ICS, inhaled corticosteroid; LABA, long-acting beta-2 agonist; LTOT, long-term oxygen therapy.

###### 

Characteristics of COPD patients with severe acute exacerbation

  Variables                                   Pulmonologist (Group A)   Internists (Group B)   *P*-value
  ------------------------------------------- ------------------------- ---------------------- ---------------
  The period before admission (days)          1 (1--10)                 2 (1--7)               0.437
  Cause                                                                                        
   Infection                                  27 (93.2)                 16 (55.2)              **0**.**001**
   Poor compliance and inhalation technique   1 (3.4)                   1 (3.4)                --
   Pollution                                  1 (3.4)                   12 (41.4)              **0**.**001**
  Location of admission                                                                        
   Ward                                       20 (68.9)                 23 (79.3)              0.539
   Intensive care unit                        9 (31.1)                  6 (20.7)               0.368
  Length of stay (days)                                                                        
   Ward                                       3.5 (1--20)               4.5 (2--11)            0.837
   Intensive care unit                        3.0 (1--7)                5.5 (2--29)            0.085
   Total                                      4.0 (1--20)               6 (2--29)              0.265
  Cost of treatment (\$)                                                                       
   Drug                                       213 (15--793)             140 (16--1,655)        0.851
   Laboratory                                 97 (3--513)               114 (0--865)           0.561
   Chest radiography                          9 (0--40)                 7 (0--25)              0.203
   Other                                      227 (80--1,574)           239 (22--4,023)        0.682
   Total                                      612 (159--2,615)          494 (578--6,793)       0.657

**Notes:** Results are expressed as n (%) or median (range). Bold values indicate *P*-value reached statistical significance (\<0.05).

###### 

Results of treatment for COPD with severe acute exacerbation

  Variables                    Pulmonologist (Group A)   Internists (Group B)   *P*-value
  ---------------------------- ------------------------- ---------------------- -----------
  Resolved                     29 (100.0)                27 (93.1)              0.150
  Dead                         0                         2 (6.9)                
  Readmission with pneumonia   0                         5 (17.2)               **0.019**

**Notes:** Results are expressed as n (%). Bold value indicates *P*-value reached statistical significance (\<0.05).

###### 

Characteristics of COPD with severe acute exacerbation requiring mechanical ventilator

  Variables                      Pulmonologist (Group A)   Internists (Group B)   *P*-value
  ------------------------------ ------------------------- ---------------------- -----------
  Mechanical ventilator (days)   1.5 (1--7)                5 (3--29)              0.005
  Length of stay (days)                                                           
   Ward                          3 (1--14)                 5.5 (4--11)            0.378
   Intensive care unit           2 (1--7)                  5 (2--29)              0.090
   Total                         3.5 (1--20)               16 (6--29)             **0.012**
  Cost of treatment (\$)                                                          
   Drug                          277 (101--648)            628 (140--1,655)       0.070
   Laboratory                    135 (12--441)             223 (140--865)         0.056
   Chest radiography             22 (0--28)                51 (26--248)           **0.022**
   Other                         134 (134--1,574)          1,296 (259--4,023)     0.055
   Total                         863 (247--2,496)          2,095 (763--6,792)     **0.049**

**Notes:** Results are expressed as median (range). Bold values indicate *P*-value reached statistical significance (\<0.05).
